|
|
 |
|
Viewing report
|
|
|
|
Serbia Pharmaceuticals and Healthcare Report Q4 2008
Business Monitor International, Nov 2008, Pages: 76
Serbia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Serbia's pharmaceuticals and healthcare industry.
We calculates that the value of pharmaceuticals sold in Serbia reached US$1.17bn in 2007. Patented products accounted for almost 50% of the market (US$569mn), followed by over-the-counter (OTC) medicines (US$325mn) and generic drugs (US$279mn).
Through to 2012, we are forecasting a compound annual growth rate (CAGR) of 12.64%. According to ALiMS data, in 2007, public spending on medicines and medical care was in the region of RD145bn (EUR1.82bn), with public healthcare facilities receiving RSD135.2bn for medical services and pharmaceuticals dispensed. Primary care accounted for around 24% of the total cost, with secondary and tertiary care accounting for 48.5% of the total. Prescription pharmaceuticals dispensed to the insured represented a cost of RSD18.35bn, or some 13.57% of the total cost of healthcare insurance, or 12.72% of the total healthcare spending. Dialysis was one of the largest areas of need, with around 2.36% of the total healthcare expenditure spent on such services.
Total healthcare expenditure in Serbia was severely affected by the dissolution of Yugoslavia in the 1990s, leaving many healthcare facilities in very poor condition by the turn of the century. An EU assessment at this time found that most hospital equipment was over 20 years old and as a result it, along with several individual countries, provided funding to help improve standards. Perishable medical equipment, such as syringes, is more often than not purchased at patients' personal expense in Serbia, which has significantly constrained market growth. Additionally, most of the equipment is old and outdated, with many modern products not registered in the country.
The prescription drug market segment is dominant, illustrating the traditional reliance on hospitals and doctors as healthcare providers In 2007, prescription medicines accounted for an estimated 87.3% of the total market by value, with this figure expected to fall to just under 85% by the end of 2012. Continued pressure on prices and the encouragement of the OTC sector will be major reasons for this loss of market share.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Serbia Pharmaceuticals and Healthcare Report Q3 2011
Serbia Pharmaceuticals and Healthcare Report Q4 2011
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Switzerland Pharmaceuticals and Healthcare Report Q4 2008
Mobility Aids & Accessories Worldwide - A Market Strategy Report
|
|
|
|
